Adrian Newman-Tancredi, PhD, DSc, will present at the forthcoming World Orphan Drug Congress to be held November 12-14, 2014 in Brussels, Belgium. Dr. Newman-Tancredi has been invited in his capacity as Chief Scientific Officer of Neurolixis to chair the session on "Innovation in the Orphan Drug Sector".

Dr. Newman-Tancredi will also give a joint presentation with Dr. Ana Paula Abdala Sheikh of Bristol University, entitled "Targeting Rett syndrome with NLX-101, a novel Orphan Medicinal Product".

Neurolixis is developing a clinical candidate, NLX-101, as a treatment for Rett syndrome, a serious orphan disorder that affects about 30 000 girls in Europe and North America. Investigation of the physiological effects of NLX-101 is being conducted by Dr. Abdala Sheik at the University of Bristol in the laboratory of Prof. Julian Paton with support from the International Rett Syndrome Foundation and the Rett Syndrome Research Trust (see previous press release).

For full details of the World Orphan Drug Congress program see the meeting website.



Please enable the javascript to submit this form

Follow Neurolixis on: